Previous Close | 119.63 |
Open | 119.41 |
Bid | 0.01 x 1100 |
Ask | 120.00 x 1100 |
Day's Range | 118.65 - 119.80 |
52 Week Range | 97.91 - 120.01 |
Volume | 160,647 |
Avg. Volume | 166,877 |
Market Cap | 4.612B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 33.49 |
EPS (TTM) | N/A |
Earnings Date | Mar 10, 2021 - Mar 15, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 102.78 |
China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that it has called an extraordinary general meeting of shareholders (the "EGM") to be held on March 1, 2021 at 10:00 a.m. (Beijing time), at the principal office of the Company located at 18th Floor, Jialong International Building, 19 Chaoyang Park Road, Chaoyang District, Beijing, China, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of November 19, 2020 (the "Merger Agreement"), among the Company, CBPO Holdings Limited ("Parent") and CBPO Group Limited ("Merger Sub"), the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands (the "Plan of Merger") and the transactions contemplated thereby, including the Merger (as defined below).
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 817 13F filings submitted by hedge funds and prominent investors. These filings show these funds’ portfolio positions as of September 30th, 2020. […]
China Biologic announced its third quarter 2020 financial results on November 24th, 2020, after the market closed. Today, you will hear from China Biologic's Chairman and CEO, Mr. Joseph Chow, who will start off the call with a review of the Company's basic operating results and report recent developments. China Biologic's CFO, Mr. Ming Yang, will be available during the Q&A session following the prepared remarks.